Stocks of CytomX Therapeutics Inc (NASDAQ:CTMX) traded higher last session on Wall Street, up 4.41% to $2.13.
CTMX stock price is now 126.47% away from the 50-day moving average and 111.91% away from the 200-day moving average. The market capitalization of the company currently stands at $335.57M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $5, H.C. Wainwright recently Upgraded its rating from Neutral to Buy for CytomX Therapeutics Inc (NASDAQ: CTMX). , while ‘Wedbush’ rates the stock as ‘Outperform’
In other news, McCarthy Sean A., CEO sold 37,656 shares of the company’s stock on Mar 18 ’25. The stock was sold for $22,556 at an average price of $0.60. Upon completion of the transaction, the CEO now directly owns 995,195 shares in the company, valued at $2.12 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 18 ’25, Chief Financial Officer Ogden Christopher sold 8,551 shares of the business’s stock. A total of $5,122 was realized by selling the stock at an average price of $0.60. This leaves the insider owning 201,026 shares of the company worth $0.43 million. A total of 2.46% of the company’s stock is owned by insiders.
During the past 12 months, CytomX Therapeutics Inc has had a low of $0.40 and a high of $2.55. As of last week, the company has a debt-to-equity ratio of 0.33, a current ratio of 1.73, and a quick ratio of 1.73. The fifty day moving average price for CTMX is $0.94058 and a two-hundred day moving average price translates $1.00516 for the stock.
The latest earnings results from CytomX Therapeutics Inc (NASDAQ: CTMX) was released for 2025-03-31. The company reported revenue of $50.92 million for the quarter, compared to $41.46 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 22.8 percent.
